Results 11 to 20 of about 61,480 (319)
Interactions between CYP3A4 and Dietary Polyphenols [PDF]
Oxidative Medicine and Cellular Longevity, 2015 The human cytochrome P450 enzymes (P450s) catalyze oxidative reactions of a broad spectrum of substrates and play a critical role in the metabolism of xenobiotics, such as drugs and dietary compounds. CYP3A4 is known to be the main enzyme involved in the
Loai Basheer, Z. Kerem
semanticscholar +3 more sources
CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. [PDF]
Pharmacogenetics and Genomics, 2016 Cytochrome P450 3A4 (CYP3A4) metabolizes 30-50% of clinically used drugs. Large interperson variability in CYP3A4 activity affects response to CYP3A4 substrate drugs. We had demonstrated that an intronic single nucleotide polymorphism rs35599367 (CYP3A4*22, located in intron 6) reduces mRNA/protein expression; however, the underlying mechanism remained
Danxin Wang, W. Sadee
semanticscholar +3 more sources
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer [PDF]
Acta Pharmacologica Sinica, 2020 Alflutinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Previous study has shown that after multiple dosages, alflutinib exhibits nonlinear pharmacokinetics and displays a time- and dose-dependent increase in the apparent clearance, probably due to its
Liu, Xiao-yun +8 more
openaire +2 more sources
Фармакокинетика и Фармакодинамика, 2022 Relevance of the study: The quantification of endogenous substances is an important task in experimental and clinical pharmacology. In the case of working with endogenous compounds, certain difficulties arise.
V. V. Smirnov +3 more
doaj +1 more source
Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement [PDF]
Advanced Pharmaceutical Bulletin, 2020 In the treatment of cancer, chemotherapy plays an important role though the efficacy of anti-cancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (
Shashank Chaturvedi +2 more
doaj +1 more source
Hepatology Communications, 2021 In drug development, a system for predicting drug metabolism and drug‐induced toxicity is necessary to ensure drug safety. Cytochrome P450 family 3 subfamily A member 4 (CYP3A4) is an important drug‐metabolizing enzyme expressed in the liver and small ...
Sayaka Deguchi +8 more
doaj +1 more source
Scientific Reports, 2021 Caco-2 cells are widely used as an in vitro intestinal epithelial cell model because they can form a monolayer and predict drug absorption with high accuracy. However, Caco-2 cells hardly express cytochrome P450 (CYP), a drug-metabolizing enzyme.
Moe Ichikawa +5 more
doaj +1 more source
Biomedicines, 2020 Several cytochrome P450 (CYP) CYP3A polymorphisms were associated with reduced enzyme function. We aimed to evaluate the influence of these alleles on the pharmacokinetic parameters (PK) of several CYP3A substrates. We included 251 healthy volunteers who
M. Saiz-Rodríguez +11 more
semanticscholar +1 more source
Di-san junyi daxue xuebao, 2022 Objective To explore the differences of postoperative patient-controlled intravenous analgesia (PCIA) with sufentanil in the patients with different CYP3A4 and CYP3A5 genotypes after laparoscopic surgery. Methods According to CYP3A4 and CYP3A5 genotypes,
GU Li +4 more
doaj +1 more source
In vitro inhibitory effects of ganoderic acid A on human liver cytochrome P450 enzymes
Pharmaceutical Biology, 2020 Context Ganoderic acid A (GAA) is usually used to prevent cancers or other diseases, which make it likely to be used with other drugs metabolized by cytochromes P450.
Shangchen Xu +5 more
doaj +1 more source